Master Governance Matrix
Quantitative Clinical Benchmarks
Standardized clinical testing schedule designed to measure efficacy and monitor organ clearance during translational evaluation.
| Biomarker / Modality | Target Compartment | Assessment Schedule | Target Clinical Endpoint |
|---|---|---|---|
|
Serum Creatine Kinase (CK)
Serum Total CK & Myoglobin
|
Sarcolemmal Integrity | Baseline, Wk 2, Wk 4, Wk 12, Wk 24 | ≥40% sustained reduction from pre-treatment baseline; validates membrane sealing and cessation of contraction-induced micro-leakage. |
|
Cardiac MRI & hs-cTnI
T1 Mapping / ECV / LVEF & hs-cTnI
|
Myocardial Protection | Baseline, Week 12, Week 24 | Absence of late gadolinium enhancement (LGE); stabilization of extracellular volume fraction (ECV) and ejection fraction; suppression of cardiac troponin leakage. |
|
Circulating Fibrotic Markers
Serum TGF-β1, MMP-9, Fibronectin
|
Anti-Fibrotic Signaling | Baseline, Week 4, Week 12 | Statistically significant reduction in active circulating TGF-β1 and matrix metalloproteinase-9, confirming NBD-mediated IKK uncoupling. |
|
Renal Clearance Profile
Urinary β2-microglobulin & Cystatin-C
|
Renal Safety | Monthly | Values within age-adjusted reference ranges; verifies absence of proximal renal tubular overload (megalin/cubilin receptor saturation). |
|
Functional Motor Batteries
NSAD / NSAA, 10M Walk, 4-Stair Climb
|
Motor Function | Baseline, Week 12, Week 24 | Score preservation or improvement on North Star assessment; stabilization of 10-meter walk/run velocity; arrest of pelvic girdle deterioration. |
Standard of Care Context
Multidisciplinary Supportive Care Standards
Best practices established by international neuromuscular consortia for managing pediatric and adult patients with β-sarcoglycanopathy.
Prescribe structured submaximal concentric exercises and aquatic therapy. Strictly avoid eccentric resistance training (e.g. running downhill, heavy plyometrics) which creates high-tension mechanical shear and tears unprotected lipid bilayers.
β-sarcoglycan is heavily expressed in cardiac tissue. Initiate annual cardiac MRI and Holter monitoring by age 8–10. Early introduction of ACE inhibitors or angiotensin receptor blockers (ARBs) is recommended at the earliest non-invasive sign of myocardial strain.
Serial spirometry (Forced Vital Capacity [FVC] sitting and supine) every 6–12 months. Early identification of nocturnal hypoventilation for timely introduction of non-invasive positive pressure ventilation (NIV), alongside scoliosis surveillance.
Next: Global Research Radar & News
Access the live PubMed and clinical trial feed, and curated research deep dives.